Navigation Links
Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
Date:6/9/2008

MOUNTAIN VIEW, Calif., June 9 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today preliminary results from its Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R) alprazolam) in patients with panic disorder. The study did not meet its two primary endpoints, which were the effect of AZ-002 on the incidence of a doxapram-induced panic attack and the effect of AZ-002 on the duration of a doxapram-induced panic attack, both as compared with placebo. There were no serious adverse events in the clinical trial, and AZ-002 was safe and well tolerated in the study patient population. AZ-002 is being developed through Symphony Allegro, a development collaboration formed between Alexza and Symphony Capital LLC in 2006.

The Company also announced today, in a separate news release, that it has completed enrollment of its first Phase 3 clinical trial with AZ-004 (Staccato loxapine)for the treatment of acute agitation in patients with schizophrenia or bipolar disorder. Alexza will host an investor conference call to discuss today's announcements on Monday, June 9, 2008 at 5:15 p.m. Eastern Time.

"The failure to reach statistical significance on the primary endpoints is disappointing, but this proof-of-concept clinical trial was designed to capture data and measurements for a number of clinical parameters in this clinical setting," said James V. Cassella, PhD, Senior Vice President, Research and Development at Alexza and chairman of the Symphony Allegro Development Board. "There is no FDA-approved therapy for the acute treatment of a panic attack or an established clinical development pathway for this potential new indication. We plan to work with our colleagues at Symphony Allegro and our ext
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
2. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
3. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
6. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
7. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
8. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
9. ASPIRE Independent Review Board Announces 10 Ways to Protect Participants Rights in Clinical Drug Trials and Optimize Results From Research
10. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
11. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) today ... 2014 financial results on Tuesday, Jan. 27, 2015, after the close ... a conference call with the investment community at 2 p.m. PT. ... Bradway , chairman and chief executive officer, and other members of ...
(Date:1/22/2015)... Institute for Clinical Research, Inc., a clinical research organization ... new textbook,  Translational Research Methods for Diabetes, Obesity and ... scientific publisher. The textbook is the first ... early phase clinical studies of new drugs for diabetes, ...
(Date:1/22/2015)... Jan. 22, 2015 Research and Markets ( ... "Infectious Disease Diagnostics Market by Product, Application, Technology, End ... their offering. , The infectious disease diagnostics ... to reach $18,156.2 million by 2019 from $12,422.8 million ...
Breaking Medicine Technology:Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... ... that a new market research report is available in ... Trends , http://www.reportlinker.com/p0164367/Immunoassay-Instruments---Global-Market-Trends.html , Immunoassay ... years due to the innovation of new technologies and ...
... ... a new market research report is available in its ... Market Analysis , http://www.reportlinker.com/p0164335/Cardiac-Pacemakers---A-World-Market-Analysis.html , ... expanding cardiovascular devices market. The worldwide cardiac pacemakers market ...
Cached Medicine Technology:Reportlinker Adds Immunoassay Instruments - Global Market Trends 2Reportlinker Adds Immunoassay Instruments - Global Market Trends 3Reportlinker Adds Immunoassay Instruments - Global Market Trends 4Reportlinker Adds Immunoassay Instruments - Global Market Trends 5Reportlinker Adds Immunoassay Instruments - Global Market Trends 6Reportlinker Adds Immunoassay Instruments - Global Market Trends 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 2Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 3Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 4Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 5Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 6Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 7Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 8Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 9Reportlinker Adds Cardiac Pacemakers - A World Market Analysis 10
(Date:1/22/2015)... (PRWEB) January 22, 2015 Padre Murphy's and ... supporter of Pro Player Health Alliance (PPHA). The ... Murphy's in getting everyone, including NFL greats, treated for obstructive ... the leading groups supporting the cause in the valley. The ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... A new white paper by The Beryl Institute ... long-term care environment as well as provides recommendations for ... “The Power of Person-Centeredness in Long-Term Care: A View ... patient, resident and family experience in long-term care and ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting the ... , Purchasing an accidental death and dismemberment rider for ... of rider provides benefits if the insured dies in an ... form of life insurance. , AD&D is not expensive ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Video Available at dietchallenge.usatoday.com, MCLEAN, Va., March 31 ... its fifth annual USA TODAY Weight-Loss Challenge.,The eight-week series ... ., Each week USA TODAY will follow the ... to their lives, and their waistlines. These,stories range from ...
... combines 2 medications , , SUNDAY, March 30 (HealthDay News) -- ... sense of a trial showing that a drug can lower ... benefit to people at high risk of heart attack and ... statin -- simvastatin -- with ezetimibe, which also lowers LDL ...
... lower restenosis risk and don,t increase mortality probability , , ... small tubing placed in diseased coronary arteries to keep ... heart attack patients, new research shows. , In the ... stents -- the drug in question retards the growth ...
... cancer deaths could be avoided with lifestyle changes, experts ... therapies that could cut cancer deaths in half. , ... recent American Cancer Society report that said as many ... with lifestyle changes, such as quitting smoking, maintaining a ...
... 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical ... the American College of Cardiology,s 57th Annual Scientific ... Among the most significant presentations are the following: ... Transplant Allograft Vasculopathy , Dr. Jeffrey ...
... services is associated with enhanced communications between families ... of life for children dying from cancer, according ... and Children,s Hospital Boston. , Published in the ... Oncology, the study,s findings also suggest that the ...
Cached Medicine News:Health News:USA TODAY Weight-Loss Challenge Returns For 5th Year With Eight Weeks of Compelling Stories and Online Features 2Health News:USA TODAY Weight-Loss Challenge Returns For 5th Year With Eight Weeks of Compelling Stories and Online Features 3Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 2Health News:NewYork-Presbyterian/Columbia physician-scientists present at ACC's 57th Annual Scientific Session 3Health News:Study finds improvement in the care of children with cancer at the end of life 2Health News:Study finds improvement in the care of children with cancer at the end of life 3